IP Library Granted Patent US 9,205,055
Granted Patent B2
US 9,205,055 · App. 14/727,997 · Granted Dec 8, 2015

Controlled release hydrocodone formulations

Inventors: Benjamin Oshlack (Boca Raton, FL); Hua-Pin Huang (Englewood Cliffs, NJ); John K. Masselink (Old Tappan, NJ); Alfred Tonelli (Congers, NY)
Assignee: Purdue Pharma L.P.
A61K9/2031A61K9/0004A61K9/141A61K9/2013A61K9/2027A61K9/2054A61K9/2072A61K9/2077A61K9/2086A61K31/194A61K31/46A61K31/485
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,205,055
App. No.
14/727,997
Granted
Dec 8, 2015
Kind
B2
Abstract

A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.

Claims (22)

1. A process for preparation of a solid oral controlled-release dosage form of hydrocodone comprising incorporating hydrocodone or a salt thereof into a controlled-release matrix by forming granules and compressing granules into a tablet such that the tablet after administration to a human patient provides a C 24 /C max ratio of about 0.55 to about 1.0 and a therapeutic effect for at least about 24 hours.

2. The process of claim 1 , wherein the controlled-release material comprises a controlled-release polymer.

3. The process of claim 2 , wherein the controlled-release polymer is selected from the group consisting of alkylcelluloses, acrylic and methacrylic acid polymers and copolymers, cellulose ethers, carboxyalkylcelluloses, and mixtures thereof.

4. The process of claim 3 , wherein the cellulose ether comprises a hydroxyalkylcellulose.

5. The process of claim 3 , wherein the acrylic and methacrylic acid polymers and copolymers are selected from the group consisting of methyl methacrylate, methyl methacrylate copolymers, ethoxyethyl methacrylates, cynaoethyl methacrylate, aminoalkyl methacrylate copolymer, poly(acrylic acid), poly(methacrylic acid), methacrylic acid alkylamine copolymer, poly(methyl methacrylate), polymethacrylate, polyacrylamide, poly(methacrylic acid anhydride), glycidyl methacrylate copolymers, and mixtures thereof.

6. The process of claim 1 , wherein the salt is a bitartrate salt of hydrocodone.

7. The process of claim 1 , comprising incorporating a gum into the controlled-release matrix.

8. The process of claim 1 , comprising incorporating a wax into the controlled release matrix.

9. The process of claim 1 , wherein from about 0.5 mg to about 1250 mg of hydrocodone or salt thereof is incorporated into the controlled-release matrix.

10. The process of claim 1 , wherein the granules are compressed into the tablet such that the tablet provides an in-vitro release of the hydrocodone when measured by the USP Basket method at 100 rpm in 700 ml aqueous buffer at a pH of 1.2 at 37° C. of from 10% to about 45% by weight hydrocodone or salt thereof released at 1 hour.

11. A process for preparation of a solid oral controlled-release dosage form of hydrocodone comprising incorporating hydrocodone or a salt thereof into a controlled-release matrix by forming granules and compressing granules into a tablet such that the tablet provides controlled release of the hydrocodone or the pharmaceutically acceptable salt thereof for a time period of from 8 to at least about 24 hours,

an in-vitro release rate of hydrocodone, when measured by the USP Basket Method at 100 rpm in 900 ml aqueous buffer at a pH of between 1.6 and 7.2 at 37° C., of from 0% to about 35% at 1 hour, from about 10% to about 70% at 4 hours, from about 20% to about 75% at 8 hours, from about 30% to about 80% at 12 hours, from about 40% to about 90% at 18 hours, and greater than about 60% at 24 hours, and,

after administration to a human patient or a population of patients a C 24 /C max ratio of about 0.55 to about 1.0.

12. The process of claim 11 , wherein the controlled-release material comprises a controlled-release polymer.

13. The process of claim 12 , wherein the controlled-release polymer is selected from the group consisting of alkylcelluloses, acrylic and methacrylic acid polymers and copolymers, cellulose ethers, carboxyalkylcelluloses, and mixtures thereof.

14. The process of claim 13 , wherein the cellulose ether comprises a hydroxyalkylcellulose.

15. The process of claim 13 , wherein the acrylic and methacrylic acid polymers and copolymers are selected from the group consisting of methyl methacrylate, methyl methacrylate copolymers, ethoxyethyl methacrylates, cynaoethyl methacrylate, aminoalkyl methacrylate copolymer, poly(acrylic acid), poly(methacrylic acid), methacrylic acid alkylamine copolymer, poly(methyl methacrylate), poly(methacrylic acid)(anhydride), polymethacrylate, polyacrylamide, poly(methacre etherylic acid anhydride), glycidyl methacrylate copolymers, and mixtures thereof.

16. The process of claim 11 , wherein the salt is a bitartrate salt of hydrocodone.

17. The process of claim 11 , comprising incorporating a gum into the controlled-release matrix.

18. The process of claim 11 , comprising incorporating a wax into the controlled release matrix.

19. The process of claim 11 , wherein from about 0.5 mg to about 1250 mg of hydrocodone or salt thereof is incorporated into the controlled-release matrix.

20. The process of claim 10 , wherein the granules are compressed into the tablet such that the tablet provides an in-vitro release of the hydrocodone when measured by the USP Basket method at 100 rpm in 700 ml aqueous buffer at a pH of 1.2 at 37° C. of from 10% to about 45% by weight hydrocodone or salt thereof released at 1 hour.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2019
From: THE P.F. LABORATORIES, INC.
To: PURDUE PHARMA L.P.
Reel/Frame 050412/0030 →
Continuity (13)
Continuation 14612483 · Feb 3, 2015
Continuation 14581175 · Dec 23, 2014
Continuation 14520032 · Oct 21, 2014
Continuation 14210565 · Mar 14, 2014
Continuation 13901069 · May 23, 2013
Continuation 13721293 · Dec 20, 2012
Continuation 13535996 · Jun 28, 2012
Continuation 12914054 · Oct 28, 2010
Division 12378586 · Feb 17, 2009
Continuation 10660349 · Sep 11, 2003
Continuation 10016651 · Oct 30, 2001
Provisional Application 60244424 · Oct 30, 2000
Related Publication 20150258089A1 · Sep 17, 2015